GPP
ABUS icon

Great Point Partners’s Arbutus Biopharma ABUS Stock Holding History

Great Point Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-668,907
Closed -$2.6M – 31
2021
Q4 		$2.6M Buy
+668,907
New +$2.6M 0.58% 33

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Great Point Partners's ABUS Position: Q1 2022 in Review

Great Point Partners sold out of Arbutus Biopharma (ABUS) in Q1 2022, closing a stake of 668,907 shares — an estimated $2.6M sold.

Great Point Partners first reported a position in ABUS in Q4 2021 and held it in 1 quarter. The position peaked at $2.6M in Q4 2021. 119 funds tracked by Wall St. Rank hold ABUS as of Q1 2022.

  • Great Point Partners reported no remaining Arbutus Biopharma position as of Q1 2022 after selling out during the quarter.
  • Great Point Partners sold 668,907 Arbutus Biopharma shares in Q1 2022, an estimated $2.6M.
  • Great Point Partners first reported a position in Arbutus Biopharma in Q4 2021 and held it in 1 quarter.
  • Great Point Partners's Arbutus Biopharma position peaked at $2.6M in Q4 2021.
  • 119 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2022.

Based on Great Point Partners's 13F filing for Q1 2022, filed 16 May 2022.